SlideShare a Scribd company logo
1 of 19
Presented By-
Nayan Jha
M.Pharm( DRA)
Poona College of Pharmacy
Bhartiya Vidhyapeeth, Pune
Present Scenario of
Clinical Trials in
India: Waking the
Sleeping Tiger
Introduction
• India is one of the major destination for conducting clinical
trials. The Drug Controller General of India (DCGI) is the
governing body responsible for all pharmaceutical-research
and regulatory issues in India.
• Clinical trials in India are controlled by 3 regulatory guidelines.
• The presentation is planned to see the scenario of clinical
trials and their trend over the last 10-12 years and also in view
of new regulatory guidelines.
15-12-2017 2
Contents
1. What is clinical trial?
2. World’s clinical trial status
3. Why India as a destination for clinical trial?
4. Growth of clinical trial in India
5. Achievements and initiatives
6. Challenges
7. Clinical trial quick facts
8. Conclusion
15-12-2017 2
1. What is Clinical trial ?
• “Any investigation in human subjects intended to discover or verify the clinical,
pharmacological and/or other pharmacodynamic effects of an investigational product(s),
and/or to identify any adverse reactions to an investigational product(s), and/or to study
absorption, distribution, metabolism, and excretion of an investigational product(s) with
the object of ascertaining its safety and/or efficacy”. (according to ICH-GCP 1.12)
• Clinical trial has four phases:
PHASE 1
(Human
Pharmacology
trial)
PHASE 2
(Exploratory
trial)
PHASE 3
(Confirmatory
trial)
PHASE 4
(Post
Marketing
trial)
15-12-2017 4
Overview of Clinical trial
International Clinical Trial Day celebrated each year on/near 20th May in
order to celebrate the day James Lind started the famous clinical trial,1747
(www.jameslindlibrary.com)
15-12-2017 5
Drug Discovery and Development
*SOURCE- R&D Cost Study Briefing, Boston
15-12-2017 6
2. World’s Clinical Trial Status
Geriatric trials have been on spotlight in countries like USA & Japan.
Paediatric trials have been on spotlight in countries like Canada and Australia.
SOURCE- https.//ClinicalTrials.gov
15-12-2017 7
3. Why India as a destination for clinical trial?
Investigators
• Large no. of specialists in different therapy segments
• Medical training in English
• Treatment protocols in line with west
Patient Population
•Large, diverse, therapy-naıve
•Large pt. pool in acute/chronic disease segment
•Increasing no. of pts in life style disorders segment, HIV, oncology
Clinical Research infrastructure
• Over 200 medical colleges
• Over 22,000 graduates per year
• World class medical/lab facilities at secondary/tertiary care centres
• Skilled computer savvy biomedical work force
Connectivity
• High quality digital connectivity
• Excellent air/surface transport facilities across country
SOURCE- Dr. Surender Singh,ClinicalTrials New Horizon—India
15-12-2017 8
*SOURCE- McKinsey report, CDSCO
Cost of carrying out Clinical research in India, Russia, China is half the
amount required in USA.
15-12-2017 9
4. Growth of clinical trial in India
*SOURCE- Clinical Trial Registry; www.clinicaltrials.gov
*SOURCE- Mc kinsey report,2016
• The Indian pharmaceutical industry is
growing at an annual rate of 11 % while
the clinical research industry is growing an
annual rate of whopping 84 %.
• India ranked third in the vaccine trials
among the study regions next to US and
EU.
• The top 10 diseases with maximum
ongoing trials in India was found to be in-
cancer, diabetes, coronary artery
disease (CAD), asthma, chronic obstructive
pulmonary disease (COPD), epilepsy,
hypertension, schizophrenia, heart failure,
HIV, malaria.
15-12-2017 10
4. Growth of clinical trial in India
• 1.3% population growth/year- rise in trials 20% by 2020.
Phase wise distribution of studies done by
various systems of medicine
State-wise maximum number of studies are done in - Maharashtra
Gujarat
Tamil Nadu
15-12-2017 11
No. of clinical trial approval
5. Achievements & Initiatives
Evolution of regulatory changes in India (2005–2017 as relevant to clinical trials)
YEAR NATURE OF REGULATION
2005-2006
• Amendment of 1988 version of
Schedule Y
• Next revision was done in 2006
2007
• CDSCO disqualifies NRA
(assessment in respect of
Regulatory Control over
vaccines discovered and
manufactured in the Country).
2009
• CDSCO qualifies NRA
• Registration of Clinical trial to
CTRI was done mandatory from
15th June.
15-12-2017 12
YEAR NATURE OF REGULATION
2013
• Introduction of SAE analysis and
timelines for reporting SAEs
• Introduction of compensation for clinical
trial related injury or death
• Various requirements conditions for
conduct of clinical trials included
• Registration of ECs with DCGI made
mandatory
• Introduction of AV recording of informed
consent process of clinical trials
• Independent ECs to oversee
Bioavailability and Bioequivalence studies
(BA/BE) for approved drug molecules
15-12-2017 13
YEAR NATURE OF REGULATION
2016
• No approval needed from DCGI when-
a) A 'new' drug undergoing a clinical trial for investigator
initiated studies (IIS) .
b) Addition of new trial site or investigator
• GCP Inspection checklist released by CDSCO
• Diagnostic laboratories & research centres can import/export
biological material without the need for an import/export license
• SUGAM- online applications for clinical trials
• Uplift of restriction of Investigator to only 3 trials rule
• New Amendment of DACA Rules,1945 came on 31st Dec
2017
• ICMR came up with the newly revised guideline “Ethical Guideline for
Biomedical Research on Human Participants” in October
15-12-2017 14
6. Challenges
New regulations bought in
severe challenges
15-12-2017 15
7. Clinical Trials Quick Facts
• RECENTLY APPROVED DRUGS IN INDIA-
Date of Approval Drug Disease
7/12/2017 Macitentan tablet Pulmonary arterial hypertension
24/11/2017 Arteolane maleate+ Piperaquine
phosphate Dispersible tablet
Acute Uncomplicated P.falciferum
& P.vivax malaria
10/11/2017
Tenofovir Fumarate capsule
Chronic Hepatitis B
• TOP 3 CRO’S IN INDIA-
QUINTILES IMS
HOLDINGS, INC.
PAREXEL International
Corporation
LABORATORY
CORPORATION OF
AMERICA HOLDINGS
15-12-2017 16
.
15-12-2017 17
• As of July 2014, the New Drug Advisory Committees (NDACs) established in
2011 were renamed Subject Expert Committees (SECs).
• In May 2017, FDA Office of International Programs held its 1st joint training
workshop for Indian regulators, academic representative and industry on ethical
standards for clinical trials.
• In August 2017, Government proposes abolishing clinical trials on proven drugs.
• Mylan and Biocon’s biosimilar trastuzumab, to be sold under the name Ogivri,
gets first US-FDA approval for the treatment of breast cancer or stomach cancer
• GlaxoSmithKline Wins FDA Approval for Shingles Vaccine “Shingrix”.
• At present, the Indian environment is again becoming conducive to
clinical trials. However, it is essential that all stakeholders work
toward common goal of conducting quality trials which assure
human subject protection while ensuring data integrity of the trial.
• The recent regulatory amendments call for a fresh breath of air in
the clinical research industry.
8. Conclusion
15-12-2017 18
‘GREAT FUTURE OF CLINICAL TRIALS
IN INDIA’
present scenario of clinical trials in India

More Related Content

What's hot

Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introduction
biinoida
 

What's hot (20)

Clinical Research
Clinical ResearchClinical Research
Clinical Research
 
CLINICAL TRIALS OF MEDICAL DEVICES
CLINICAL TRIALS OF MEDICAL DEVICESCLINICAL TRIALS OF MEDICAL DEVICES
CLINICAL TRIALS OF MEDICAL DEVICES
 
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxCLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
 
GOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICESGOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICES
 
New drugs and clinical trials rules, 2019_ Dilip Kawane
New drugs and clinical trials rules, 2019_ Dilip KawaneNew drugs and clinical trials rules, 2019_ Dilip Kawane
New drugs and clinical trials rules, 2019_ Dilip Kawane
 
Opportunities in Clinical Research
Opportunities in Clinical ResearchOpportunities in Clinical Research
Opportunities in Clinical Research
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
SCHEDULE Y : Latest Amendment
SCHEDULE Y : Latest AmendmentSCHEDULE Y : Latest Amendment
SCHEDULE Y : Latest Amendment
 
CRA/ Monitor Roles and Responsibilities
CRA/ Monitor Roles and ResponsibilitiesCRA/ Monitor Roles and Responsibilities
CRA/ Monitor Roles and Responsibilities
 
Clinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLSClinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLS
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Schedule Y
Schedule YSchedule Y
Schedule Y
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introduction
 
Main Responsibilities of a CRO Pharma
Main Responsibilities of a CRO PharmaMain Responsibilities of a CRO Pharma
Main Responsibilities of a CRO Pharma
 
Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)
 
Cra responsebility
Cra responsebilityCra responsebility
Cra responsebility
 
Documentation clinical trial
Documentation clinical trialDocumentation clinical trial
Documentation clinical trial
 
Cfr 21 part 312
Cfr 21 part 312 Cfr 21 part 312
Cfr 21 part 312
 
Contract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma FieldContract Research Organisations- CRO in Pharma Field
Contract Research Organisations- CRO in Pharma Field
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentation
 

Similar to present scenario of clinical trials in India

Similar to present scenario of clinical trials in India (20)

crppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdfcrppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdf
 
Introduction to Clinical Research Regulations
Introduction to Clinical Research RegulationsIntroduction to Clinical Research Regulations
Introduction to Clinical Research Regulations
 
Laws and Guidelines on Clinical Trials in India.pptx
Laws and Guidelines on Clinical Trials in India.pptxLaws and Guidelines on Clinical Trials in India.pptx
Laws and Guidelines on Clinical Trials in India.pptx
 
Principles of drug trial in cardiology
Principles of drug trial in cardiology Principles of drug trial in cardiology
Principles of drug trial in cardiology
 
RDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory UpdateRDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory Update
 
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trialsICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
 
Regulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMTRegulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMT
 
Cr and opportunities by bhumika
Cr and opportunities by bhumikaCr and opportunities by bhumika
Cr and opportunities by bhumika
 
NACCHO 2018 National Conference – Project Reference Group Meeting
NACCHO 2018 National Conference – Project Reference Group MeetingNACCHO 2018 National Conference – Project Reference Group Meeting
NACCHO 2018 National Conference – Project Reference Group Meeting
 
FDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures ActFDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures Act
 
A questionnaire based survey on awareness of clinical trials among general po...
A questionnaire based survey on awareness of clinical trials among general po...A questionnaire based survey on awareness of clinical trials among general po...
A questionnaire based survey on awareness of clinical trials among general po...
 
A questionnaire based survey on awareness of clinical trials among general po...
A questionnaire based survey on awareness of clinical trials among general po...A questionnaire based survey on awareness of clinical trials among general po...
A questionnaire based survey on awareness of clinical trials among general po...
 
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGYEvidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
 
Dr. Andy Lee
Dr. Andy LeeDr. Andy Lee
Dr. Andy Lee
 
The Impact of Real-World Data in Pharmacovigilance and Regulatory Decision-Ma...
The Impact of Real-World Data in Pharmacovigilance and Regulatory Decision-Ma...The Impact of Real-World Data in Pharmacovigilance and Regulatory Decision-Ma...
The Impact of Real-World Data in Pharmacovigilance and Regulatory Decision-Ma...
 
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the VeilClinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
 
Big Data and Stratified Medicine
Big Data and Stratified MedicineBig Data and Stratified Medicine
Big Data and Stratified Medicine
 
STREAM TWO: Fiona Frappier, Canada’s regulatory approach to drugs for rare di...
STREAM TWO: Fiona Frappier, Canada’s regulatory approach to drugs for rare di...STREAM TWO: Fiona Frappier, Canada’s regulatory approach to drugs for rare di...
STREAM TWO: Fiona Frappier, Canada’s regulatory approach to drugs for rare di...
 
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessClinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
 
WJPR 6039
WJPR 6039 WJPR 6039
WJPR 6039
 

Recently uploaded

Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near MeRussian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
mriyagarg453
 
Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024
Sheetaleventcompany
 
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetThoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetSambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetMangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetRajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetjabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetOzhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetbhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetBareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
mahaiklolahd
 
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetMuzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetnagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in LahoreBest Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
Deny Daniel
 
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetThrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
 

Recently uploaded (20)

(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
 
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near MeRussian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
Russian Call Girls in Noida Pallavi 9711199171 High Class Call Girl Near Me
 
Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024
 
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
 
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetThoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetSambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sambalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetMangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mangalore Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Dehradun Call Girls 8854095900 Call Girl in Dehradun Uttrakhand
Dehradun Call Girls 8854095900 Call Girl in Dehradun  UttrakhandDehradun Call Girls 8854095900 Call Girl in Dehradun  Uttrakhand
Dehradun Call Girls 8854095900 Call Girl in Dehradun Uttrakhand
 
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetRajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetjabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
jabalpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetOzhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ozhukarai Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetbhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetBareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
ooty Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
Call Girl in Bangalore 9632137771 {LowPrice} ❤️ (Navya) Bangalore Call Girls ...
 
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetMuzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Muzaffarpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetnagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in LahoreBest Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
Best Lahore Escorts 😮‍💨03250114445 || VIP escorts in Lahore
 
Kolkata Call Girls Miss Inaaya ❤️ at @30% discount Everyday Call girl
Kolkata Call Girls Miss Inaaya ❤️ at @30% discount Everyday Call girlKolkata Call Girls Miss Inaaya ❤️ at @30% discount Everyday Call girl
Kolkata Call Girls Miss Inaaya ❤️ at @30% discount Everyday Call girl
 
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetThrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 

present scenario of clinical trials in India

  • 1. Presented By- Nayan Jha M.Pharm( DRA) Poona College of Pharmacy Bhartiya Vidhyapeeth, Pune Present Scenario of Clinical Trials in India: Waking the Sleeping Tiger
  • 2. Introduction • India is one of the major destination for conducting clinical trials. The Drug Controller General of India (DCGI) is the governing body responsible for all pharmaceutical-research and regulatory issues in India. • Clinical trials in India are controlled by 3 regulatory guidelines. • The presentation is planned to see the scenario of clinical trials and their trend over the last 10-12 years and also in view of new regulatory guidelines. 15-12-2017 2
  • 3. Contents 1. What is clinical trial? 2. World’s clinical trial status 3. Why India as a destination for clinical trial? 4. Growth of clinical trial in India 5. Achievements and initiatives 6. Challenges 7. Clinical trial quick facts 8. Conclusion 15-12-2017 2
  • 4. 1. What is Clinical trial ? • “Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy”. (according to ICH-GCP 1.12) • Clinical trial has four phases: PHASE 1 (Human Pharmacology trial) PHASE 2 (Exploratory trial) PHASE 3 (Confirmatory trial) PHASE 4 (Post Marketing trial) 15-12-2017 4
  • 5. Overview of Clinical trial International Clinical Trial Day celebrated each year on/near 20th May in order to celebrate the day James Lind started the famous clinical trial,1747 (www.jameslindlibrary.com) 15-12-2017 5
  • 6. Drug Discovery and Development *SOURCE- R&D Cost Study Briefing, Boston 15-12-2017 6
  • 7. 2. World’s Clinical Trial Status Geriatric trials have been on spotlight in countries like USA & Japan. Paediatric trials have been on spotlight in countries like Canada and Australia. SOURCE- https.//ClinicalTrials.gov 15-12-2017 7
  • 8. 3. Why India as a destination for clinical trial? Investigators • Large no. of specialists in different therapy segments • Medical training in English • Treatment protocols in line with west Patient Population •Large, diverse, therapy-naıve •Large pt. pool in acute/chronic disease segment •Increasing no. of pts in life style disorders segment, HIV, oncology Clinical Research infrastructure • Over 200 medical colleges • Over 22,000 graduates per year • World class medical/lab facilities at secondary/tertiary care centres • Skilled computer savvy biomedical work force Connectivity • High quality digital connectivity • Excellent air/surface transport facilities across country SOURCE- Dr. Surender Singh,ClinicalTrials New Horizon—India 15-12-2017 8
  • 9. *SOURCE- McKinsey report, CDSCO Cost of carrying out Clinical research in India, Russia, China is half the amount required in USA. 15-12-2017 9
  • 10. 4. Growth of clinical trial in India *SOURCE- Clinical Trial Registry; www.clinicaltrials.gov *SOURCE- Mc kinsey report,2016 • The Indian pharmaceutical industry is growing at an annual rate of 11 % while the clinical research industry is growing an annual rate of whopping 84 %. • India ranked third in the vaccine trials among the study regions next to US and EU. • The top 10 diseases with maximum ongoing trials in India was found to be in- cancer, diabetes, coronary artery disease (CAD), asthma, chronic obstructive pulmonary disease (COPD), epilepsy, hypertension, schizophrenia, heart failure, HIV, malaria. 15-12-2017 10
  • 11. 4. Growth of clinical trial in India • 1.3% population growth/year- rise in trials 20% by 2020. Phase wise distribution of studies done by various systems of medicine State-wise maximum number of studies are done in - Maharashtra Gujarat Tamil Nadu 15-12-2017 11 No. of clinical trial approval
  • 12. 5. Achievements & Initiatives Evolution of regulatory changes in India (2005–2017 as relevant to clinical trials) YEAR NATURE OF REGULATION 2005-2006 • Amendment of 1988 version of Schedule Y • Next revision was done in 2006 2007 • CDSCO disqualifies NRA (assessment in respect of Regulatory Control over vaccines discovered and manufactured in the Country). 2009 • CDSCO qualifies NRA • Registration of Clinical trial to CTRI was done mandatory from 15th June. 15-12-2017 12
  • 13. YEAR NATURE OF REGULATION 2013 • Introduction of SAE analysis and timelines for reporting SAEs • Introduction of compensation for clinical trial related injury or death • Various requirements conditions for conduct of clinical trials included • Registration of ECs with DCGI made mandatory • Introduction of AV recording of informed consent process of clinical trials • Independent ECs to oversee Bioavailability and Bioequivalence studies (BA/BE) for approved drug molecules 15-12-2017 13
  • 14. YEAR NATURE OF REGULATION 2016 • No approval needed from DCGI when- a) A 'new' drug undergoing a clinical trial for investigator initiated studies (IIS) . b) Addition of new trial site or investigator • GCP Inspection checklist released by CDSCO • Diagnostic laboratories & research centres can import/export biological material without the need for an import/export license • SUGAM- online applications for clinical trials • Uplift of restriction of Investigator to only 3 trials rule • New Amendment of DACA Rules,1945 came on 31st Dec 2017 • ICMR came up with the newly revised guideline “Ethical Guideline for Biomedical Research on Human Participants” in October 15-12-2017 14
  • 15. 6. Challenges New regulations bought in severe challenges 15-12-2017 15
  • 16. 7. Clinical Trials Quick Facts • RECENTLY APPROVED DRUGS IN INDIA- Date of Approval Drug Disease 7/12/2017 Macitentan tablet Pulmonary arterial hypertension 24/11/2017 Arteolane maleate+ Piperaquine phosphate Dispersible tablet Acute Uncomplicated P.falciferum & P.vivax malaria 10/11/2017 Tenofovir Fumarate capsule Chronic Hepatitis B • TOP 3 CRO’S IN INDIA- QUINTILES IMS HOLDINGS, INC. PAREXEL International Corporation LABORATORY CORPORATION OF AMERICA HOLDINGS 15-12-2017 16
  • 17. . 15-12-2017 17 • As of July 2014, the New Drug Advisory Committees (NDACs) established in 2011 were renamed Subject Expert Committees (SECs). • In May 2017, FDA Office of International Programs held its 1st joint training workshop for Indian regulators, academic representative and industry on ethical standards for clinical trials. • In August 2017, Government proposes abolishing clinical trials on proven drugs. • Mylan and Biocon’s biosimilar trastuzumab, to be sold under the name Ogivri, gets first US-FDA approval for the treatment of breast cancer or stomach cancer • GlaxoSmithKline Wins FDA Approval for Shingles Vaccine “Shingrix”.
  • 18. • At present, the Indian environment is again becoming conducive to clinical trials. However, it is essential that all stakeholders work toward common goal of conducting quality trials which assure human subject protection while ensuring data integrity of the trial. • The recent regulatory amendments call for a fresh breath of air in the clinical research industry. 8. Conclusion 15-12-2017 18 ‘GREAT FUTURE OF CLINICAL TRIALS IN INDIA’

Editor's Notes

  1. DCGI- three regulatory guides- Schedule y- DACA 1945, revise2005 GCP-CDSCO,2002, ICHE6 Ethical guidelinefor biomedical reseach on human participants by ICMR, 2006
  2. From 2009
  3. INVESTIGATORS- Medical training in English, (iii) 600,000 English speaking physicians (iv) PG training from Europe/US PATEINT POP-
  4. Why china ? ?
  5. Steady rise in diseases = rise in patient pool=
  6. definition of a clinical trial and clear identification of responsibilities of sponsor, investigator and Ecs NRA______ document system for quality assurance was developed and Common Technical Document (CTD) format for filing the applications in accordance to ICH guidelines
  7. Point3- req- IEC approval, registration with CTRI, submission of annual status report….. 2013- lag period….. AV relaxation – only for vulnerable person,new mol entity, anti-HIV,anti-leprosy(audio)
  8. potential overlap between the academic and regulatory purposes of the trial, they should notify the office of the DCGI. If the IEC does not hear from the DCGI within 30 days, it should be presumed that no permission is needed from the licensing authority They only need to submit an undertaking about the safe transfer and disposal of the biological material
  9. workload rise by 20% annually and manpower is at same rate(9 officials= 20,000 applications/year) multiplicity=+overlapping= lengthy turnaround approval, under enforcement of quality studs.
  10. 9/11- MIDOSTAURIN CAPSULE- acute myeliod leukaemia 10/11/2017- Tenofovir Fumarate capsule ---Chronic Hepatitis B 24/11- 6 months to 12 yrs LAB COOP- LABCORP DIGNOSTICS+ COVANCE DRUG DEVELPMENT
  11. The move to abolish clinical trials of proven drugs will reduce time taken to introduce new drugs in India to just 45 days from 5-6 years . have been approved and marketed for at least two years in the European Union, UK, US, Australia, Canada and Japan FORMER_ dr.surender singh